Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Eli Lilly and Company
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
An Open Label Study Comparing Exenatide with Basal Insulin in Achieving an HbA1c of <_7.4% with Minimum Weight Gain, in Type 2 Diabetes Patients who are not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone
The primary objective of this study is to determine whether exenatide given subcutaneously twice daily provides better HbA1c control, with minimal weight gain, than basal insulin given subcutaneously...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with Radiographic Axial Spondyloarthritis
Compare both ixekizumab regimens (80 mg every 2 weeks or 80 mg every 4 weeks vs placebo in patients with active radiographic axial spondyloarthritis at week 16.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer
The primary objective of the phase I part of this study is to determine the recommended Phase 2 dose of pemetrexed, cisplatin, and involved-field radiotherapy in the treatment of patients with LS-SCLC...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
To test the hypothesis that the ACR50 response after 24 weeks for the smallest dose that achieves at least 95% of the maximal efficacy (ED95) of LY2127399 is significantly greater than for placebo, wh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 5 ans
A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
The primary objective of this study is to compare the OS of pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks to the OS of single-agent cisplatin 75 mg/m2 every 3 weeks in patients with HNC t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
This is an open-label, multicenter, nonrandomized Phase 1b study of oral administration of LY2157299 in combination with gemcitabine followed by a randomized, double-blind, Phase 2 study of oral administration of LY2157299 monohydrate in combination with gemcitabine versus gemcitabine plus placebo
Phase 2: To compare overall survival (OS) in patients with Stage II-IV unresectable pancreatic cancer when treated with the combination of LY2157299 monohydrate and gemcitabine with that of gemcitab...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A study of nab-paclitaxel and gemcitabine with or without olaratumab for treatment of pancreatic cancer that has spread to other parts of the body
Phase Ib: To determine a recommended Phase 2 dose of olaratumab in combination with nab-paclitaxel and gemcitabine Phase II: To compare the efficacy of olaratumab plus nab-paclitaxel and gemcitabi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A clinical trial in patients with moderate to severe plaque psoriasis comparing the efficacy and safety of taking a drug called Ixekizumab either every 4 weeks or every 2 weeks
To compare the efficacy of continuous every 2-week (Q2W) dosing versus continuous every 4-week (Q4W) dosing of ixekizumab in the treatment of patients with moderate-to-severe plaque psoriasis (Ps), as...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus
The primary objective of this study is to test the hypothesis that LY2963016 administered once daily (QD) is noninferior to Lantus administered QD, as measured by change in hemoglobin A1c (HbA1c) from...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 5 ans
A clinical trial to compare Insulin Lispro and Insulin Aspart for use in pumps in patients with Type 1 Diabetes Mellitus
1) Day 6 of 6 days of pump reservoir in-use of Humalog 6D was noninferior to Day 6 of 6 days of pump reservoir in-use of Aspart 6D with regards to 7-point daily mean self-monitored blood glucose (SMBG...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant